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ABSTRACT
Heart disease is a major cause of death in both men and women in industrialized countries. In fact, many individuals,
who develop heart disease, have normal cholesterol and blood pressure levels. It suggests that other risk factors
may also play a role. Iron (Fe), zinc (Zn) and copper (Cu) may promote CHD by increasing lipid peroxidation and
causing oxidant-induced damage in various organs. These minerals are essential as cofactors for functional enzymes
in the body. The hypothesis that Fe and Cu depletion protects against ischemic heart disease has generated significant
debate, but this hypothesis cannot be rejected until stronger evidence that high Fe stores increase the incidence of
CHD or death from myocardial infarction is proven. This research was aimed to find out the levels of Fe, Cu, and Zn
plasma as risk factors for heart disease patients, compared with those in hyperlipidemic patients and controls. In
this study, we examined the Fe, Zn and Cu levels in plasma of CHD patients, hyperlipidemic patients, and healthy
controls by atomic absorption spectrophotometer. Thirty five CHD patients, 31 hyperlipidemic patients, and 26
healthy controls. Age, body weight, body height, BMI, systolic and diastolic blood pressure of each group were not
significantly different (p > 0.05). There were higher cholesterol and lower HDL-C levels in CHD patients compared
with those in hyperlipidemic patients and controls. There were significantly higher triglyceridemia level in hyperlipidemic
patients compared to those in CHD patients and controls. Iron level in CHD patients were not significantly different
than those in hyperlipidemic patients and controls. Zinc level in CHD patients were not significantly different compared
with those in controls, but in hyperlipidemic patients, they were significantly lower than those in CHD patients and
controls. Copper level in CHD and hyperlipidemic patients were significantly lower than those in controls. In this
research, it could be concluded that the decrease in Cu level might be one of the risk factors of CHD.
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INTRODUCTION
Until now, studies on iron (Fe) and copper (Cu)
as risk factors of CHD is still controversial.1-3
Hypothesis suggested in 1981 and known as “iron
hypothesis” that the decrease in Fe level might
prevent ischemic heart disease had generated
debates. Studies were continued to prove the
hypothesis. It was reported that there was a
relationship between serum ferritin level and the risk
of heart attack.4 Abnormal Fe stores might caused
damage in various organs induced by oxidants. Iron
stores in the heart were involved in the development
of heart fibrosis. In CHD, there was an increase in
Fe level in intimal lesion, compared with healthy
control.3,4
Zinc and Cu are essential minerals in the human
body. More than 100 types of enzymes need Zn as
cofactors for metabolic pathways important for
growth and development. In addition, there was also
evidence that Zn and Cu were also involved in the
pathogenesis of CHD. Low Zn level was assumed
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to cause atherosclerosis.5,6 Patients with dilated
cardiomyopathy had higher level of serum Cu and
lower of serum Zn than healthy controls.7
Copper is the third most essential mineral after
Fe and Zn in human body.5 Free Cu can not be
found in considerable amount in the body, and
almost all are bound by transport proteins, storage
proteins, and Cu-containing enzymes. Copper is
important for various functions of enzymes,
including cytochrome oxidase, superoxide
dysmutase (SOD) functioning as antioxidants,
tyrosinase which active in pigmentation, dopamine
hydroxylase producing cathecolamines, lysyl-
oxidase that forms collagen and elastin, coagulation
factor V, and ceruloplasmin functioning as oxidant,
and participate in Fe metabolism and Cu transport.
Outside the body, Cu is known as pro-oxidants and
is often used to oxidize LDL. Ceruloplasmin protein
which contained Cu had been found to stimulate
oxidized-LDL in test tube, causing several experts
assumed that the increase in Cu level would increase
the risk of atherosclerosis by increasing the oxidation
of LDL, but the available evidences were limited.
In addition, SOD and ceruloplasmin were known
to have antioxidant activities, causing several experts
assumed that Cu deficiency would increase the risk
of CHD, instead of the Cu excess.8,9 In the body,
Cu was changed into cupro- and cupri- forms. The
ability of Cu to give electrons explained its important
role in redox reaction and in catching free radicals.5,10
Lack of Cu intake caused abnormality in the
formation of blood vessel wall and caused
pathological changes, causing CHD. It was also
shown that Cu/Zn ratio had an inverse correlation
with blood pressure.11
The aim of the study was to find out the plasma
levels of Fe, Cu, and Zn plasma of CHD patients,
compared with those in hyperlipidemic patients and
healthy controls.
MATERIALS AND METHODS
Subjects
Subjects of the study were CHD patients from
Dr. Sardjito Hospital Yogjakarta who were
diagnosed by internists, and samples were taken by
consecutive random sampling. Controls were
hyperlipidemic patients who visited Dr. Sardjito
Hospital Yogjakarta and did not suffer from CHD.
Hyperlipidemic patients were those who had blood
lipid levels outside the normal range. Normal controls
were elderlies who joined elderly sport group in
Banteng village, Sinduadi, Sleman,Yogjakarta, who
had blood lipid levels in the normal range.Adetailed
explanation of the procedures was given to all
subjects and written informed consents were
obtained from all of them. The protocol of this study
has been approved by the Health Research Ethics
Committee of Faculty of Medicine, Gadjah Mada
University, Yogyakarta.
Chemical analysis
Ten mL blood sample was taken from each
subject after fasting, and put into mineral-free test
tubes containing anticoagulant heparin. Iron, Cu,
and Zn plasma levels were measured with atomic
absoprtion spectrophotometer (AAS). Body weight,
body height, systolic and diastolic blood pressure
were measured. Total cholesterol, triglyceride, LDL-
C, and HDL-C levels were measured with enzymatic
method (CHOD-PAP) with Dyasis kit. Patient was
grouped as dyslipidemic if his/her HDL-C level was
less than 40 mg%, LDL-C level was more than 160
mg%, tryglyceride level was more than 160 mg%,
and total cholesterol level was more than 200 mg%,
and control was subject who had normal lipid levels.
Data analysis
The results from were analyzed with analysis
of variance and t-test. Result was considered
significant if p < 0.05.
RESULTS
In this study, there were 35 CHD patients (21
men and 14 women) between the ages of 40-75
years, 31 hyperlipidemic patients (12 men and 19
women) between the ages of 32-73 years, and 26
controls (15 men and 11 women) between the ages
of 42-74 years. Data of age, body weight, body
height, BMI (Body Mass Index), and blood lipid
profiles of CHD patients, hyperlipidemic patients
and controls are shown in TABLE 1, FIGURE 1
and 2, whereas significance of lipid profiles between
CHD patients, hyperlipidemic patients, and controls
are shown in TABLE 2.
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TABLE 1. Average age, body weight, body height, BMI, blood pressure and lipid profiles of CHD patients,
hyperlipidemic patients, and controls
CHD patients
(35)
Hyperlypidemic
patients (31)
Controls
(26)
p
Age (yrs) 61.24 ±9.31 56.84 ± 8.30 57.19 ± 8.50 >0,05
Body weight (kg) 63.00 ±9.00 62.42 ± 11.07 62.56 ± 9.30 >0,05
Body height (m) 162.3 ± 5.0 157.2 ± 37.6 161.4± 5.3 >0,05
BMI 23.8 ± 3.0 25.2 ± 3.7 24.0 ± 3.35 >0,05
Systolic BP (mmHg) 140.61 ± 17.13 138.06 ± 19.95 137.31 ± 19.56 >0,05
Diastolic BP (mmHg) 83.94 ± 10.29 87.10 ± 9.57 89.04 ± 12.96 >0,05
HDL-C (mg/dL) 45.142 ± 14.684 48.816 ± 10.014 50.833 ± 7.429 >0,05
LDL-C (mg/dL) 126.98 ± 38.272 143.39 ± 35.025 97.430 ± 25.010 >0,05
Cholesterol (mg/dL) 199.740 ± 32.974 154.490 ± 66.470 154.710 ± 37.580 <0,05
Triglyceride (mg/dL) 132.900 ± 71.069 239.010 ± 48.816 117.560 ± 51.476 <0,05
FIGURE 1. Age, body weight, body height, BMI, and blood
pressure of CHD patients, hyperlipidemic patients, and
controls
TABLE 2. Significance of lipid profiles between CHD
patients, hyperlipidemic patients, and controls
CHD-
Hyperlipidemia
CHD-
Controls
Hyperlipidemia-
Controls
HDL-C 0.618 0.226 0.223
LDL-C 0.465 0.052 0.243
Cholesterol 0.145 0.019 0.151
Triglyceride 0.695 0.030 0.074
Data in TABLE 1 shown that age, body weight,
body height, BMI, and blood pressure of CHD
patients, hyperlipidemic patients, and controls were
not significantly different (p > 0.05). The lowest
average of HDL-C level was found in CHD patients
and was not significantly different with
hyperlipidemic patient and controls (p > 0.05). The
highest average of LDL-C level was found in hyper-
FIGURE 2. HDL-C, LDL-C, cholesterol, and triglyceride
levels of CHD patients, hyperlipidemic patients, and controls
lipidemic patients but not significantly different with
CHD patients and controls (p>0.05). Cholesterol
levels of CHD patients were significantly higher than
those in controls (p < 0.05), but there were not
significantly different between CHD patients and
hyperlipidemic patients also between hyperlipidemic
patients and controls (p > 0.05). Triglyceride levels
in hyperlipidemic patients were not significantly
different with those in CHD patients and controls
(p> 0.05), but there were significantly different
between CHD patients and controls (p< 0.05).
The total number of CHD and hyperlipidemic
patients who had dyslipidemia are shown in FIGURE
3, while the significance and Odd Ratio of blood
lipoprotein abnormality in CHD patients and
hyperlipidemic patients are shown in TABLE 3.
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TABLE 3. Significance and Odd Ratio of blood lipoprotein abnormality in CHD patients and hyperlipidemic patients
CHD patients
(n = 35)
Hyperlipidemic
patients (n= 31) p OR
HDL-C (< 35 mg/dL) 6 (17%) 2 (6%) 0.172 3.00
LDL-C (> 165 mg/dL) 7 (20%) 6 (19%) 0.948 1.04
Cholesterol (> 200 mg/dL) 15 (43%) 12 (39%) 0.734 1.19
Triglyceride (> 200 mg/dL) 4 (11%) 29 (94%) 0.000 0.01
TABLE 3 showed that there were 43% CHD
patients had hypercholesterolemia, while in
hyperlipidemic patients, there were 94% had high
level of triglyceride in blood. Odd ratio showed that
patients with low HDL-C level would have 3 times
increased risk of CHD compared with patients with
normal HDL-C level. High concentrations of LDL-
C and cholesterol in CHD patients were not different
and not risk factors for CHD. Triglyceride level in
FIGURE 3 : The total number of CHD and hyperlipidemic
patients who had dyslipidemia
hyperlipidemic patients was high and significantly
different with CHD and this high level was not risk
factor for CHD.
The Fe, Zn, and Cu levels of CHD patients,
hyperlipidemic patients, and controls are shown in
FIGURE 4 and TABLE 4, while the significance of
Fe,Zn, andCu levels in CHDpatients, hyper-lipidemic
patients, and controls are shown in TABLE 5.
FIGURE 4. Iron, Zn, and Cu levels of CHD patients,
hyperlipidemic patients, and controls
TABLE 4. Iron, Zn, and Cu levels of CHD patients, hyperlipidemic patients, and controls
CHD patients Hyperlipidemic patients Controls
Iron (Fe) μg/dL 106.65 ± 70.86 266.61 ± 228.42 141.25 ±132.87
Zinc (Zn)μg/dL 153.66 ±51.91 110.49 ± 43.34 156.70 ±34.17
Copper (Cu)μg/dL 134.90 ± 55.19 136.14 ± 84.84 209.73 ± 41.76
TABLE 5. Significance of Fe, Zn, and Cu levels in CHD patients, hyperlipidemic patients, and controls
CHD -
Hyperlipidemia CHD-Control
Hyperlipidemia-
Controls
Iron (Fe)μg/dL 0.615 0.536 0.438
Zinc (Zn)μg/dL 0.049 0.944 0.048
Copper (Cu)μg/dL 0.613 0.046 0.042
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TABLE 4 and 5 showed that Fe level in CHD
was not significantly different (p > 0.05) with those
in hyperlipidemic patients and controls. It showed
that plasma Fe level was not a risk factor of CHD.
Zinc level was lower in hyperlipidemic patients and
significantly different (p < 0.05) with those in CHD
patients and controls, but Zn level between CHD
patients and controls was not significantly different
(p > 0.05). It could be concluded that Zn was not a
risk factor for CHD, but risk factor for high blood
lipid levels. Meanwhile, Cu level in CHD and
hyperlipidemic patients was significantly lower than
those in controls (p < 0.05), while Cu level between
CHD and hyperlipidemic patients was not
significantly different (p > 0.05). It could be
concluded that Cu might be one of the risk factors
of CHD and high blood lipid level.
DISCUSSION
Studies on animals and human have reported
that Cu was related to lipid metabolism and that Cu
deficiency significantly decreased plasma cholesterol
level. Those were consistent with the results of this
study which reported that low Cu level caused an
increase in cholesterol level in CHD and
hyperlipidemic patients. Besides, the increase in
cholesterol level would increase LDL-C level and
decrease HDL-C level, and increase the risk of CHD.
Study on Cu-deficient rats showed that their life
expectancy were decreased to 75%. The heart of
patients who died of ischemic heart diseases showed
hypertrophy, fibrosis, and edema. These pathological
changes were also found in Cu-deficient animals.5
Copper deficiency can contribute to some
cardiovascular risks. Aortic aneurysms may be
genetic condition that related to a defect in the ability
to store or absorb Cu. Copper deficiency, due to its
effect on ceruloplasmin, may cause an Fe-deficiency
anemia which can only be corrected with Cu
supplementation as it impairs Fe absorption, reduces
heme synthesis and increases Fe accumulation in
storage tissues.12
From anatomical, chemical and physiological
points of view, there were similarities between Cu-
deficient animals and ischemic heart disease patients.
There were an increase in cholesterol level, uric
acid level, and blood pressure, and a decrease in
glucose tolerance in Cu deficiency.5,8,13,14 Copper
deficiency increased the level of lipid peroxide in
liver mitochondria. Besides, SOD activity was
decreased, and there were also a decrease in catalase
and glutathione peroxidase activities, other
antioxidants that did not need Cu for their activities.
In addition, Cu deficiency decreased the activity of
SOD and prostacyclin synthesis in aorta, and
increased lipoprotein sensitivity and heart muscle
against peroxidation, which gave strong evidence
of important role of Cu in the prevention of free-
radicals-induced damage on cardiovascular system.5
Salonen was the first who reported that there
was a significant relationship between serum ferritin
level and the risk of heart attack. The study showed
that men with serum ferritin200g/L had twice
increased risk to have heart attack.4
A study by Brandsch et al.15 in rats which were
given Fe-high diet genetically did not affect their
antioxidant status, but it increased the formation of
cholesterol oxidation products, particularly if they
were given diet high in double-bond unsaturated fatty
acid. Sempos2 and Bozzini et al.1 showed that there
were no strong evidence supporting this. A study
by Ishizaka et al.16 on rats which were given
angiotensin II infusion for 7 days showed Fe
deposition in the heart, which probably involved in
the development of heart fibrosis induced by
angiotensin II. In addition, the high level of Fe might
increase the formation of neointima in the condition
of high angiotensin II level in circulation, but it was
not occurred in cathecolamine administration. Study
by Stadler et al.3 who observed patients with arterial
diseases showed the increase in Fe and Cu levels in
injured intima compared with healthy subjects. The
study showed that there was Fe accumulation in
lesion, that may support the development of the
disease. Study on post-menopausal women who
drank alcohol and given by Fe and Zn diet showed
that high heme Fe intake might be dangerous, but
Zn intake was beneficial on the mortality of
cardiovascular system with the availability of
compounds that interfered with Fe hemostatis such
as alcohol.17 It was estimated that the increase in
Fe level caused inflammation, that probably would
increase reactive-C protein level often found in heart
disease patients.
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CONCLUSION
This study concluded that:
1. In CHD patients, there were an increase in cho-
lesterol level and decrease in HDL-C level, while
in hyperlipidemic patients, there were an in-
crease in triglyceride level.
2. The decrease in Zn level was risk factor of
hyperlipidemia.
3. The decrease in Cu level was a risk factor of
CHD and hyperlipidemia.
ACKNOWLEDGMENT
The authors would like to thank the Dean of
Faculty of Medicine, Gadjah Mada University and
the Director and Staff of Internal Medicine, Dr.
Sardjito Hospital for their permission and assistence
to perform this research.
REFERENCES
1. Bozzini C, Girelli D,Tinazzi E, Oliveri O, Stranieri C, Bassi
A, Trabetti E, Faccini G, Pignatti PF, Corrocher R.
Biochemical and genetic markers of iron status and the
risk of coronary artery disease : an angiography-based
study. Clin Chem 2002; 48: 622-8.
2. Sempos CT. Do body iron stores increase the risk of
developing coronary heart disease. Am J Clin Nutr 2002;
76(3): 501 – 3.
3. Stadler N, Lindner RA, Davies MJ. Direct detection and
quantification of transition metal ions in human
atherosclerotic plaques : evidence for the presence of
elevated levels of iron and copper. Arterioscler Thromb
Vasc Biol 2004; 24: 949-50.
4. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J,
Seppanen R, Salonen R. High stores iron levels are
associated with excess risk of myocardial infarction in
Eastern Finnish men, Circulation 1992; 86: 803 – 11.
5. Gissen AS. Copper: the maligned minerlal. Vibrant life
2006; in http://www. oralchelation.com/technical/
copper1.htm
6. Kelishadi R,Alikhassy H,Amiri M. Zinc and copper status
in children with high family risk of premature
cardiovascular disease. Ann Saudi Med 2002; 22: 5-6.
7. Wilson L. Copper toxicity syndrome. Center for
Develompent 2009; 1-24.
8. Kok FJ, Van Duijn CM, Hofman A, Van der Voet GB, De
Wolff FA, Paays CH, Valkenburg HA. Serum copper and
zinc and the risk of death from cancer and cardiovascular
disease. Am J Epid 1988; 128(2): 352-9.
9. Roland A, Patterson RA, Leake DS. Measurement of
copper-binding sites on low density lipoprotein.Arterioscler
Thromb Vasc Biol 2001; 21: 594-602.
10. Turnlund JR, Jacob RA, Keen CL, Strain JJ, Kelley DS,
Domek JM, KeyesWR, Ensunsa JL, Lykkesfeldt J, Coulter
J. Long-termhigh copper intake: effectson indexesof copper
status,antioxidant status, and immunefunction inyoungmen.
Am J Clin Nutr 2004; 79(6):1037-44.
11. Sullivan JL. Irin and the genetics of cardiovascular
disease. Circulation 1999; 100: 1260 – 3.
12. Watts DL. The nutritional relationships of copper. J
Orthomol Med 1989; 4(2): 99-108.
13. Clevay LM. Lack of a recommended dietary allowance
for copper may be hazardous to your health. JAm College
Nutr 1998; 17(4): 322-6.
14. Klevay LM. Cardiovascular disease from copper
deficiency -a history. J Nutr 2000; 130(2S Suppl): 489S-
92S.
15. Brandsch C, Ringseis R, Eder K. High dietary iron
concentrations enhance the formation of cholesterol
oxidation products in the liver of adult rats fed salmon oil
with minimal effects on antioxidants status. J Nutr 2002;
132(8): 2263 – 9.
16. Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui
S, Mori I, Ohno M, Nagai R. Iron overload augments
angiotensin II-induced cardiac fibrosis and promotes
neointima formation. Circulation 2002; 106(14): 1840-6.
17. Lee DH, Folsom AR, Jacobs DR. Iron, zinc, and alcohol
consumption and mortality from cardiovascular disease :
the Iowa Women’s health study. Am J Clin Nutr 2005;
81(4): 787 – 91.
